First product covered is a proprietary protein vaccine component.

Merck & Co. signed a multiproduct commercial license agreement for Pfenex Expression Technology™, a Pseudomonas-based tool from Dowpharma. 


According to Dowpharma, the first product under the agreement is a proprietary protein vaccine component for which a high-yield production strain and a fully-scalable fermentation process were successfully developed in less than six months.  The process was subsequently transferred to Merck and will be used to support its related future regulatory filings.


Under the agreement, which encompasses additional future protein products, Merck receives a nonexclusive license to use Pfenex Expression Technology for the development and manufacture of proteins for use in human medicinal products. 

Previous articleIkaria and Investor Group to Acquire INO Therapeutics for $670M
Next articleCureDM Enhances Diabetes-Reversing Candidate